Cost of hemophilia A in Brazil: a microcosting study

Ana Paula Beck Silva Etges, Nayê Balzan Schneider, Erica Caetano Roos, Miriam Allein Zago Marcolino, Margareth Castro Ozelo, Mariana Midori Takahashi Hosokawa Nikkuni, Luany Elvira Mesquita Carvalho, Tatyane Oliveira Rebouças, Monica Hermida Cerqueira, Veronica Mata and Carisi Anne Polanczyk ()
Additional contact information
Ana Paula Beck Silva Etges: National Institute of Science and Technology for Health Technology Assessment (IATS) - CNPq/Brazil (project: 465518/2014-1)
Nayê Balzan Schneider: National Institute of Science and Technology for Health Technology Assessment (IATS) - CNPq/Brazil (project: 465518/2014-1)
Erica Caetano Roos: National Institute of Science and Technology for Health Technology Assessment (IATS) - CNPq/Brazil (project: 465518/2014-1)
Miriam Allein Zago Marcolino: National Institute of Science and Technology for Health Technology Assessment (IATS) - CNPq/Brazil (project: 465518/2014-1)
Margareth Castro Ozelo: University of Campinas
Mariana Midori Takahashi Hosokawa Nikkuni: University of Campinas
Luany Elvira Mesquita Carvalho: Ceará Hematology and Hemotherapy Center-HEMOCE
Tatyane Oliveira Rebouças: Ceará Hematology and Hemotherapy Center-HEMOCE
Monica Hermida Cerqueira: Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti-HEMORIO
Veronica Mata: Roche Produtos Farmacêuticos
Carisi Anne Polanczyk: National Institute of Science and Technology for Health Technology Assessment (IATS) - CNPq/Brazil (project: 465518/2014-1)

Health Economics Review, 2024, vol. 14, issue 1, 1-8

Abstract: Abstract Background Patients with Hemophilia are continually monitored at treatment centers to avoid and control bleeding episodes. This study estimated the direct and indirect costs per patient with hemophilia A in Brazil and evaluated the cost variability across different age groups. Methods A prospective observational research was conducted with retrospective data collection of patients assisted at three referral blood centers in Brazil. Time-driven Activity-based Costing method was used to analyze direct costs, while indirect costs were estimated based on interviews with family and caregivers. Cost per patient was analyzed according to age categories, stratified into 3 groups (0–11;12–18 or older than 19 years old). The non-parametric Mann-Whitney test was used to confirm the differences in costs across groups. Results Data from 140 hemophilia A patients were analyzed; 53 were 0–11 years, 29 were 12–18 years, and the remaining were older than 19 years. The median cost per patient per year was R$450,831 (IQR R$219,842; R$785,149; $174,566), being possible to confirm age as a cost driver: older patients had higher costs than younger’s (p = 0.001; median cost: 0–11 yrs R$299,320; 12–18 yrs R$521,936; ≥19 yrs R$718,969). Conclusion This study is innovative in providing cost information for hemophilia A using a microcosting technique. The variation in costs across patient age groups can sustain more accurate health policies driven to increase access to cutting-edge technologies and reduce the burden of the disease.

Keywords: Hemophilia A; Health Care costs; Economic evaluation (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-024-00539-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00539-x

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-024-00539-x

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().